Management of paclitaxel-induced neurotoxicity

Oncology Reviews

Volumn 4, Issue 2, 2010, Pages 107-115

  Bhutani, Manisha ^a   Colucci, Philomena M ^a   Laird Fick, Heather ^a   Conley, Barbara A ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Neuropathy; Paclitaxel; Supportive care; Taxane

Indexed keywords

CAPECITABINE; CAPSAICIN; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CREMOPHOR; CYCLOSPORIN; DOCETAXEL; DULOXETINE; ENOXAPARIN; EPIRUBICIN; EPOTHILONE DERIVATIVE; GABAPENTIN; IMMUNOMODULATING AGENT; IRINOTECAN; LIDOCAINE; OPIATE; OXCARBAZEPINE; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; PREGABALIN; PROTEASOME INHIBITOR; VINCA ALKALOID;

AGED; ALCOHOL CONSUMPTION; ANALGESIA; ARTHRALGIA; AXONAL INJURY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DAILY LIFE ACTIVITY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DYSESTHESIA; ELECTROMYOGRAM; ELECTROMYOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FOOT EDEMA; GAIT; HEPATOGRAPHY; HUMAN; KIDNEY DISEASE; LIMB WEAKNESS; LIVER METASTASIS; LOW DRUG DOSE; MALE; MICROTUBULE; MICROTUBULE ASSEMBLY; MOTOR ACTIVITY; MUSCLE CRAMP; MYALGIA; NAUSEA; NERVE CELL; NERVE CONDUCTION DISORDER; NERVE EXCITABILITY; NEUROLOGIC EXAMINATION; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PAIN; PALLIATIVE THERAPY; PALPATION; PARANEOPLASTIC SYNDROME; PARESTHESIA; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PERONEUS NERVE PARALYSIS; PHYSIOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PREMEDICATION; PRIORITY JOURNAL; PROPRIOCEPTION; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK FACTOR; SCORING SYSTEM; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SKIN TINGLING; SOLID TUMOR; TAXUS BREVIFOLIA; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT DURATION; WHEELCHAIR;

EID: 77954564996     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-010-0048-x     Document Type: Review

References (58)

1. Kuroi K, Shimozuma K, Ohashi Y et al (2008) Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR02 study). Support Care Cancer 17:1071-1080
2. Papadimitriou CA, Fountzilas G, Bafaloukos D et al (2008) Paclitaxel, topotecan, and carboplatin in metastatic endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Gynecol Oncol 111:27-34
3. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259
4. Loprinzi CL, Maddocks-Christianson K, Wolf SL et al (2007) The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 13:399-403
5. Perry JR, Warner E (1996) Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology 46:1596-1599
6. Rook J, Rosser T, Fangusaro J, Finlay J (2008) Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. Pediatr Blood Cancer 50:699-700
7. Kobayashi N, Mundel P (1998) A role of microtubules during the formation of cell processes in neuronal and non-neuronal cells. Cell Tissue Res 291:163-174
8. Masurovsky EB, Peterson ER, Crain SM, Horwitz SB (1983) Morphological alterations in dorsal root ganglion neurons and supporting cells of organotypic mouse spinal cord-ganglion cultures exposed to taxol. Neuroscience 10:491-509
9. Lipton RB, Apfel SC, Dutcher JP et al (1989) Taxol produces a predominantly sensory neuropathy. Neurology 39:368-373
10. Apfel SC, Lipton RB, Arezzo JC, Kessler JA (1991) Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 29:87-90
11. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F (2000) Description of a short-term taxol-induced nociceptive neuropathy in rats. Brain Res 887:239-249
12. Haushier FH (2008) Chemotherapy induced peripheral neuropathy. In: Perry MC (ed) The chemotherapy source book, 4th edn. Wolters Kluwer Health/Lippincott Williams and Wilkins, Baltimore, pp 234-244
13. van Zuylen L, Verweij J, Sparreboom A (2001) Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19:125-141
14. Windebank AJ, Blexrud MD, de Groen PC (1994) Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 268:1051-1056
15. de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA (1987) Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med 317:861-866
16. Brat DJ, Windebank AJ, Brimijoin S (1992) Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther 261:803-810
17. Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM (1996) Motor neuropathy due to docetaxel and paclitaxel. Neurology 47:115-118
18. Bitton RJ, Figg WD, Reed E (1995) A preliminary risk-benefit assessment of paclitaxel. Drug Saf 12:196-208
19. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15
20. Capri G, Munzone E, Tarenzi E et al (1994) Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 86:1099-1101
21. Tibaldi C, Pazzagli I, Berrettini S, De Vito A (1998) A case of ototoxicity in a patient with metastatic carcinoma of the breast treated with paclitaxel and vinorelbine. Eur J Cancer 34:1133-1134
22. Scripture CD, Figg WD, Sparreboom A (2006) Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol 4:165-172
23. Nabholtz JM, Gelmon K, Bontenbal M et al (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867
24. Winer EP, Berry DA, Woolf S et al (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol 22:2061-2068
25. Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 non overexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649
26. Smith RE, Brown AM, Mamounas EP et al (1999) Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J ClinOncol 17:3403-3411
27. Nuijen B, Bouma M, Schellens JH, Beijnen JH (2001) Progress in the development of alternative pharmaceutical formulations of taxanes. Invest New Drugs 19:143-153
28. Terwogt JM, Nuijen B, Huinink WW, Beijnen JH (1997) Alternative formulations of paclitaxel. Cancer Treat Rev 23:87-95
29. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803
30. Fountzilas G, Kalofonos HP, Dafni U et al (2004) Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 15:1517-1526 (Pubitemid 39409743)
31. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR (1994) Peripheral neuropathy from taxol and cis-platin combination chemotherapy: clinical and electrophysiolog-ical studies. Ann Neurol 35:304-311
32. Gogas H, Shapiro F, Aghajanian C et al (1996) The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol 61:22-26
33. Vasey PA, Jayson GC, Gordon A et al (2004) Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682-1691
34. National Cancer Institute: Common Terminology Criteria for Adverse Events v 3.0. http://ctep.cancer.gov/forms/CTCAEv3.pdf
35. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
36. Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207-214
37. Bril V (1999) NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol 41(Suppl 1):8-13
38. Franse LV, Valk GD, Dekker JH, Heine RJ, van Eijk JT (2000) 'Numbness of the feet' is a poor indicator for polyneuropathy in type 2 diabetic patients. Diabet Med 17:105-110
39. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA (2003) Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-tax-ane). Cancer 98:822-831
40. Cull A, Howat S, Greimel E et al (2001) Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37:47-53
41. Monk BJ, Huang HQ, Cella D et al (2005) Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 23:4617-4625
42. Wenzel L, Huang HQ, Monk BJ et al (2005) Quality-of-life comparisons in a randomized trial of interval secondary cytore-duction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 23:5605-5612
43. Olney RK (1998) Clinical trials for polyneuropathy: the role of nerve conduction studies, quantitative sensory testing, and auto-nomic function testing. J Clin Neurophysiol 15:129-137
44. Forsyth PA, Balmaceda C, Peterson K et al (1997) Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 35:47-53
45. Perkins BA, Olaleye D, Zinman B et al (2001) Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 24:250-256
46. Jebsen RH, Taylor N, Trieschmann RB et al (1969) An objective and standardized test of hand function. Arch Phys Med Rehabil 50:311-319
47. Meneilly GS, Cheung E, Tessier D et al (1993) The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 48:M117-M121
48. Galer BS (1998) Painful polyneuropathy. Neurol Clin 16:791-812
49. Jin HW, Flatters SJ, Xiao WH, Mulhern HL, Bennett GJ (2008) Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 210:229-237
50. Openshaw H, Beamon K, Synold TW et al (2004) Neurophysi-ological study of peripheral neuropathy after high-dose paclit-axel: lack of neuroprotective effect of amifostine. Clin Cancer Res 10:461-467
51. Loven D, Levavi H, Sabach G et al (2009) Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Eur J Cancer Care (Engl) 18:78-83
52. Argyriou AA, Chroni E, Koutras A et al (2005) Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64:26-31 (Pubitemid 40082932)
53. Melli G, Taiana M, Camozzi F et al (2008) Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol 214:276-284
54. Hayakawa K, Sobue G, Itoh T, Mitsuma T (1994) Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro. Life Sci 55:519-525
55. Lewis ME, Neff NT, Contreras PC et al (1993) Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 124:73-88
56. Seidman AD, Hudis CA, Albanel J et al (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361
57. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ (1995) Paclitaxel-induced neuropathy. Ann Oncol 6:489-494
58. Nguyen VH, Lawrence HJ (2004) Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol 22:1767-1769